These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 22418743

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
    Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.
    Arthritis Res Ther; 2011 Jun 20; 13(3):R94. PubMed ID: 21689401
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis.
    Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J.
    Ann Rheum Dis; 2004 Jun 20; 63(6):665-70. PubMed ID: 15037444
    [Abstract] [Full Text] [Related]

  • 6. Which patients with ankylosing spondylitis should be treated with tumour necrosis factor inhibiting therapy? A survey among Dutch rheumatologists.
    Landewé R, Rump B, van der Heijde D, van der Linden S.
    Ann Rheum Dis; 2004 May 20; 63(5):530-4. PubMed ID: 15082483
    [Abstract] [Full Text] [Related]

  • 7. MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis.
    Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J.
    Ann Rheum Dis; 2008 Sep 20; 67(9):1276-81. PubMed ID: 18006539
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis.
    Barkham N, Kong KO, Tennant A, Fraser A, Hensor E, Keenan AM, Emery P.
    Rheumatology (Oxford); 2005 Oct 20; 44(10):1277-81. PubMed ID: 16105913
    [Abstract] [Full Text] [Related]

  • 12. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis.
    Maksymowych WP, Poole AR, Hiebert L, Webb A, Ionescu M, Lobanok T, King L, Davis JC.
    J Rheumatol; 2005 Oct 20; 32(10):1911-7. PubMed ID: 16206346
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical studies on bone-related outcome and the effect of TNF-α blocking therapy in ankylosing spondylitis.
    Arends S, Spoorenberg A, Brouwer E, van der Veer E.
    Curr Opin Rheumatol; 2014 May 20; 26(3):259-68. PubMed ID: 24625371
    [Abstract] [Full Text] [Related]

  • 16. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH, Heldmann F, Rudwaleit M, Listing J, Appel H, Braun J, Sieper J.
    Arthritis Rheum; 2010 May 20; 62(5):1290-7. PubMed ID: 20461780
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH, Rudwaleit M, Listing J, Sieper J.
    Ann Rheum Dis; 2009 Nov 20; 68(11):1701-7. PubMed ID: 19029168
    [Abstract] [Full Text] [Related]

  • 18. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
    Braun J, Baraliakos X, Listing J, Fritz C, Alten R, Burmester G, Krause A, Schewe S, Schneider M, Sörensen H, Zeidler H, Sieper J.
    Ann Rheum Dis; 2008 Mar 20; 67(3):340-5. PubMed ID: 17967831
    [Abstract] [Full Text] [Related]

  • 19. ASDAS, a highly discriminatory ASAS-endorsed disease activity score in patients with ankylosing spondylitis.
    van der Heijde D, Lie E, Kvien TK, Sieper J, Van den Bosch F, Listing J, Braun J, Landewé R, Assessment of SpondyloArthritis international Society (ASAS).
    Ann Rheum Dis; 2009 Dec 20; 68(12):1811-8. PubMed ID: 19060001
    [Abstract] [Full Text] [Related]

  • 20. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept.
    Davis JC, Van der Heijde DM, Dougados M, Braun J, Cush JJ, Clegg DO, Inman RD, de Vries T, Tsuji WH.
    J Rheumatol; 2005 Sep 20; 32(9):1751-4. PubMed ID: 16142873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.